

Non-clinical study of NRT-YHD-001 as macrophage immune check point blocker in liver cancer

NEORNAT, Inc.



ONCOLOGY	Preclinical
Product Type	Antisense miRNA (miRNA inhibitor)
Indication	Liver cancer
Target	Let-7i-5p
MoA(Mechanism of Action)	NRT-YHD-001 is an RNA liver cancer treatment pipeline with the mechanism of restores the production of TSP1 in liver cancer tissue, binds TSP1 to CD47 of cancer cells, and activating macrophages to treat liver cancer.
Competitiveness	First in class
Development Stage	Preclinical
Route of Administration	Intravenous injection